A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients

Daihei Kida, Nobunori Takahashi, Atsushi Kaneko, Yuji Hirano, Takayoshi Fujibayashi, Yasuhide Kanayama, Masahiro Hanabayashi, Yuichiro Yabe, Hideki Takagi, Takeshi Oguchi, Takefumi Kato, Koji Funahashi, Takuya Matsumoto, Masahiko Ando, Yachiyo Kuwatsuka, Eiichi Tanaka, Hidekata Yasuoka, Yuko Kaneko, Shintaro Hirata, Kosaku MurakamiYasumori Sobue, Tsuyoshi Nishiume, Mochihito Suzuki, Yutaka Yokota, Kenya Terabe, Shuji Asai, Naoki Ishiguro, Toshihisa Kojima

Research output: Contribution to journalArticlepeer-review

Abstract

This study aimed to evaluate the effectiveness of abatacept (ABA) by anti-cyclic citrullinated peptide (ACPA) status on disease activity as well as radiographic progression in patients with rheumatoid arthritis (RA) in clinical settings. A retrospective cohort study was conducted using data from a multicenter registry. Data from a total of 553 consecutive RA patients treated with intravenous ABA were included. We primarily compared the status of disease activity (SDAI) and radiographic progression (van der Heijde modified total Sharp score: mTSS) between the ACPA-negative (N = 107) and ACPA-positive (N = 446) groups. ‘ACPA positive’ was defined as ≥ 13.5 U/mL of anti-CCP antibody. Baseline characteristics between groups were similar. The proportion of patients who achieved low disease activity (LDA; SDAI ≤ 11) at 52 weeks was significantly higher in the ACPA-positive group. Multivariate logistic regression analysis identified ACPA positivity as an independent predictor for achievement of LDA at 52 weeks. Drug retention rate at 52 weeks estimated by the Kaplan–Meier curve was significantly higher in the ACPA-positive group. Achievement rate of structural remission (ΔmTSS ≤ 0.5) at 52 weeks was similar between groups. ABA treatment demonstrated a significantly higher clinical response and higher drug retention rate in ACPA-positive patients. Progression of joint destruction was similar between the ACPA-negative and ACPA-positive groups. Close attention should be paid to joint destruction even in patients showing a favorable response to ABA, especially when the ACPA status is positive.

Original languageEnglish
Article number19717
JournalScientific reports
Volume10
Issue number1
DOIs
Publication statusPublished - 2020 Dec

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients'. Together they form a unique fingerprint.

Cite this